2. Biktarvy


Active ingredients: bictegravir  
Disease: HIV  
Peak sales estimate: $6 billion  
Approved: Feb. 7, 2018
Company: Gilead Sciences 

The scoop: Facing mounting pressure on its critical hepatitis C business, Gilead Sciences won a timely FDA nod for HIV combo drug Biktarvy in February. The drug, which will face off in the field against GlaxoSmithKline’s ViiV Healthcare and its new Juluca, carries blockbuster commercial expectations. Consensus estimates are for $6 billion in peak sales, but one analyst predicts the drug could generate as much as $10 billion. Biktarvy combines the novel integrase inhibitor bictegravir with Gilead's own Descovy, a combo of emtricitabine and tenofovir alafenamide. The approval comes as Gilead’s hep C franchise comes under increasing competitive pressure, hurting Gilead’s pricing power in the field.  — Eric Sagonowsky

2. Biktarvy

Suggested Articles

A phase 3 study of NuCana’s lead drug was halted because a monitoring committee deemed it unlikely to succeed.

The filing follows data from Japanese phase 3 trials that assessed the oral HIF-PHI in chronic kidney disease patients.

The Allen Institute found major differences in human and mouse brain cells, which could guide the design of drugs for brain diseases.